Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 272

1.

Cyclin D1 Loss Distinguishes Prostatic Small Cell Carcinoma from Most Prostatic Adenocarcinomas.

Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks JL, Gupta N, Epstein JI, Netto GJ, Isaacs WB, Luo J, Mehra R, Vessella RL, Karnes RJ, Schaeffer E, Davicioni E, De Marzo AM, Lotan TL.

Clin Cancer Res. 2015 Aug 5. pii: clincanres.0744.2015. [Epub ahead of print]

PMID:
26246306
2.

Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.

Kaukoniemi KM, Rauhala HE, Scaravilli M, Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL, Visakorpi T.

Cancer Med. 2015 Jul 1. doi: 10.1002/cam4.486. [Epub ahead of print]

3.

Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.

Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, Coleman R, Nguyen H, Nelson PS, Corey E, Snyder LA, Vessella RL, Morrissey C, Lam HM.

PLoS One. 2015 Jun 19;10(6):e0130565. doi: 10.1371/journal.pone.0130565. eCollection 2015.

4.

Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.

Annala M, Kivinummi K, Tuominen J, Karakurt S, Granberg K, Latonen L, Ylipää A, Sjöblom L, Ruusuvuori P, Saramäki O, Kaukoniemi KM, Yli-Harja O, Vessella RL, Tammela TL, Zhang W, Visakorpi T, Nykter M.

Oncotarget. 2015 Mar 20;6(8):6235-50.

5.

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H.

Int J Oncol. 2015 Apr;46(4):1560-72. doi: 10.3892/ijo.2015.2860. Epub 2015 Jan 30.

PMID:
25634071
6.

Reprogramming of prostate cancer cells--technical challenges.

Borges GT, Vêncio EF, Vêncio RZ, Vessella RL, Ware CB, Liu AY.

Curr Urol Rep. 2015 Jan;16(1):468. doi: 10.1007/s11934-014-0468-4. Review.

PMID:
25404182
7.

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.

Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS.

PLoS One. 2014 Oct 30;9(10):e111545. doi: 10.1371/journal.pone.0111545. eCollection 2014.

8.

Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E.

Prostate. 2015 Feb 15;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18.

PMID:
25327986
9.

Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways.

Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C.

Oncotarget. 2014 Oct 30;5(20):9939-51.

10.

Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer.

Lam HM, Ouyang B, Chen J, Ying J, Wang J, Wu CL, Jia L, Medvedovic M, Vessella RL, Ho SM.

Endocr Relat Cancer. 2014;21(6):903-14. doi: 10.1530/ERC-14-0402. Epub 2014 Oct 6.

PMID:
25287069
11.

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.

Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, Salipante SJ, Milbank J, Yu M, Grady WM, Tait JF, Corey E, Vessella RL, Walsh T, Shendure J, Nelson PS.

Nat Commun. 2014 Sep 25;5:4988. doi: 10.1038/ncomms5988.

12.

Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM.

Cancer Lett. 2014 Sep 1;351(2):272-80. doi: 10.1016/j.canlet.2014.06.014. Epub 2014 Jul 3.

PMID:
24998678
13.

The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow.

Lam HM, Vessella RL, Morrissey C.

Drug Discov Today Technol. 2014 Mar;11:41-7. doi: 10.1016/j.ddtec.2014.02.002. Review.

14.

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P.

Cancer Res. 2014 Apr 15;74(8):2270-82. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20.

15.

Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.

Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL, Morrissey C.

Clin Exp Metastasis. 2014 Feb;31(2):247-56. doi: 10.1007/s10585-013-9625-2. Epub 2013 Nov 17.

16.

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.

Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E.

PLoS One. 2013 Oct 25;8(10):e78881. doi: 10.1371/journal.pone.0078881. eCollection 2013. Erratum in: PLoS One. 2014;9(8):e106797.

17.

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.

18.

Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a.

Ahmed F, Shiraishi T, Vessella RL, Kulkarni P.

Oncol Rep. 2013 Dec;30(6):2963-8. doi: 10.3892/or.2013.2789. Epub 2013 Oct 8.

PMID:
24100420
19.

Absolute quantification by droplet digital PCR versus analog real-time PCR.

Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M.

Nat Methods. 2013 Oct;10(10):1003-5. doi: 10.1038/nmeth.2633. Epub 2013 Sep 1.

20.

Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.

Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M.

PLoS One. 2013 Jul 30;8(7):e69239. doi: 10.1371/journal.pone.0069239. Print 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk